Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 62, Issue 4, 2003, Pages 363-367

  Parkkinen, Laura ^a,b   Soininen, Hilkka ^a   Alafuzoff, Irina ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Alzheimer disease; Amygdaloid complex; Lower brainstem; Nucleus basalis of Meynert; Substantia nigra; synuclein

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN MAPPING; BRAIN STEM; COGNITIVE DEFECT; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LEWY BODY; MAJOR CLINICAL STUDY; MEYNERT BASAL NUCLEUS; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

EID: 0037383760     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/62.4.363     Document Type: Article

References (20)

1. Trojanowski JQ, Lee VM. Transgenic models of tauopathies and synucleinopathies. Brain Pathol 1999;9:733-39
2. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001;12:2085-90
3. Lopez OL, Hamilton RL, Becker JT, Wisniewski S, Kaufer DI, DeKosky ST. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology 2000;54:1780-87
4. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity. Neurology 1990;40:1-8
5. Ince PG, McArthur FK, Bjertness E, Torvik A, Candy JM. Edwardson JA. Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions. Dementia 1995;6:162-68
6. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000;100:285-90
7. Schmidt ML, Martin JA, Lee VM, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol 1996;91:475-81
8. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-70
9. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353-57
10. Hamilton RL. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-84
11. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: Morphology and its relationship to tau aggregation. Brain Res 2001;888:287-96
12. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-26
13. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: An update. J Neural Transm Suppl 2000;59: 185-212
14. Iseki E OT, Suzuki K, Akiyama H, Ikeda K. A pathological study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathology 1995;15:112-16
15. Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996;212:111-14
16. Parkkinen L, Soininen H, Laakso M, Alafuzoff I. Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001;27:314-25
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
18. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
19. Togo T, Cookson N, Dickson DW. Argyrophilic grain disease: Neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol 2002;12:45-52
20. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-39